Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INP12 in advanced solid tumors
NCT06589401Phase 1Recruiting
- Sponsor
- InnoUp Farma
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INP12 in solid tumor and breast cancer, sponsored by InnoUp Farma. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of INP12 Adverse Events at 28 days. Started Sep 2022; status: recruiting.
02
Drugs
INP12
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT06589401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589401.